We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+1.18%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$254M
AUM Growth
+$704K
(+0.28%)
Cap. Flow
+$22.4M
Cap. Flow
% of AUM
8.85%
Top 10 Holdings %
Top 10 Hldgs %
43.68%
Holding
90
New
20
Increased
18
Reduced
11
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$9.28M |
| 2 |
Takeda Pharmaceutical
TAK
|
+$9.02M |
| 3 |
SIEN
Sientra, Inc.
SIEN
|
+$8.62M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$8.05M |
| 5 |
Humana
HUM
|
+$7.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$13.8M |
| 2 |
Gilead Sciences
GILD
|
+$10.1M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$9.55M |
| 4 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$5.99M |
| 5 |
Evolent Health
EVH
|
+$5.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.86% |
| 2 | Technology | 6.14% |
| 3 | Miscellaneous | 5.87% |
| 4 | Industrials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
AnaptysBio
ANAB
$1.63B
| – | – |
-6,082
| Closed | -$444K |
|
52
Axsome Therapeutics
AXSM
$11.2B
| – | – |
-52,268
| Closed | -$744K |
|
53
Bausch Health
BHC
$2.11B
| – | – |
-104,344
| Closed | -$2.58M |
|
54
Centene
CNC
$33.1B
| – | – |
-54,995
| Closed | -$2.92M |
|
55
CVS Health
CVS
$115B
| – | – |
-11,036
| Closed | -$595K |
|
|
DVAX
56
DELISTED
Dynavax Technologies
DVAX
| – | – |
-41,288
| Closed | -$302K |
|
57
Elevance Health
ELV
$89.8B
| – | – |
-9,084
| Closed | -$2.61M |
|
|
58
Evolent Health
EVH
$415M
| – | – |
-418,728
| Closed | -$5.27M |
|
|
59
Gilead Sciences
GILD
$187B
| – | – |
-155,793
| Closed | -$10.1M |
|
60
Haemonetics
HAE
$4.9B
| – | – |
-6,691
| Closed | -$585K |
|
61
Henry Schein
HSIC
$9.48B
| – | – |
-10,503
| Closed | -$631K |
|
|
62
Icon
ICLR
$13.1B
| – | – |
-100,874
| Closed | -$13.8M |
|
63
Krystal Biotech
KRYS
$10B
| – | – |
-61,155
| Closed | -$2.01M |
|
64
LivaNova
LIVN
$4.29B
| – | – |
-42,312
| Closed | -$4.12M |
|
65
Medtronic
MDT
$119B
| – | – |
-35,579
| Closed | -$3.24M |
|
66
Molina Healthcare
MOH
$10.7B
| – | – |
-5,830
| Closed | -$828K |
|
67
Ocular Therapeutix
OCUL
$2.23B
| – | – |
-716,124
| Closed | -$2.84M |
|
68
PTC Therapeutics
PTCT
$5.68B
| – | – |
-16,903
| Closed | -$636K |
|
69
PUT
Invesco QQQ Trust
QQQ
$482B
| – | – |
-16,600
| Closed | -$2.98M |
|
70
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$804B
| – | – |
-37,100
| Closed | -$10.5M |
|
71
Teladoc Health
TDOC
$1.14B
| – | – |
-13,153
| Closed | -$731K |
|
72
Tenet Healthcare
THC
$21.1B
| – | – |
-121,823
| Closed | -$3.51M |
|
73
Thermo Fisher Scientific
TMO
$243B
| – | – |
-10,500
| Closed | -$2.87M |
|
74
Vericel Corp
VCEL
$2.05B
| – | – |
-123,111
| Closed | -$2.16M |
|
75
Viking Therapeutics
VKTX
$3.42B
| – | – |
-178,448
| Closed | -$1.77M |
|
Similar funds
UVM
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
Endurant Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Endurant Capital Management held 90 positions worth $254M, up 0.28% from $253M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Endurant Capital Management deployed $22.4M of net new capital in Q2 2019, opening 20 new positions and adding to 18 existing holdings. Its largest new stake was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 76% a quarter earlier, followed by Technology and Miscellaneous.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $9.55M trimmed.
- Endurant Capital Management's largest Q2 2019 buy was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M.
- Endurant Capital Management added most to Takeda Pharmaceutical in Q2 2019, an estimated $9.02M increase.
- Endurant Capital Management's biggest Q2 2019 reduction was Bristol-Myers Squibb, cutting an estimated $9.55M.
- Endurant Capital Management fully exited Icon in Q2 2019, selling an estimated $13.8M.
- Endurant Capital Management's ten largest holdings make up 44% of its $254M portfolio in Q2 2019.
- Endurant Capital Management opened 20 new positions and closed 40 in Q2 2019.
- Endurant Capital Management's portfolio value rose 0.28% quarter-over-quarter to $254M.
Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.